TrialAnnals of the rheumatic diseases2007

Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.

J Gratacós et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.